Price T Rowe Associates Inc Kal Vista Pharmaceuticals, Inc. Transaction History
Price T Rowe Associates Inc
- $816 Billion
- Q1 2024
A detailed history of Price T Rowe Associates Inc transactions in Kal Vista Pharmaceuticals, Inc. stock. As of the latest transaction made, Price T Rowe Associates Inc holds 22,142 shares of KALV stock, worth $270,132. This represents 0.0% of its overall portfolio holdings.
Number of Shares
22,142
Previous 21,198
4.45%
Holding current value
$270,132
Previous $260,000
1.15%
% of portfolio
0.0%
Previous 0.0%
Shares
10 transactions
Others Institutions Holding KALV
# of Institutions
129Shares Held
46.5MCall Options Held
113KPut Options Held
72K-
Vr Adviser, LLC New York, NY6.25MShares$76.2 Million6.36% of portfolio
-
Suvretta Capital Management, LLC New York, NY4.19MShares$51.1 Million2.13% of portfolio
-
Tang Capital Management LLC San Diego, CA4.13MShares$50.3 Million5.96% of portfolio
-
Frazier Life Sciences Management, L.P. Menlo Park, CA3.69MShares$45 Million2.3% of portfolio
-
Adage Capital Partners Gp, L.L.C. Boston, MA2.58MShares$31.4 Million0.06% of portfolio
About KalVista Pharmaceuticals, Inc.
- Ticker KALV
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 24,602,000
- Market Cap $300M
- Description
- KalVista Pharmaceuticals, Inc., a clinical stage pharmaceutical company, discovers, develops, and commercializes small molecule protease inhibitors for diseases with unmet needs. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME); and oral p...